GlobeNewswire Inc | Apr 26, 2021 07:42PM EDT

April 26, 2021

SAN FRANCISCO, April 26, 2021 (GLOBE NEWSWIRE) -- Hagens Berman urges Emergent BioSolutions Inc. (NYSE: EBS) investors with $100k or more losses to submit your losses now.

Class Period: July 6, 2020 - Mar. 31, 2021Lead Plaintiff Deadline: June 18, 2021Visit:www.hbsslaw.com/investor-fraud/EBSContact an Attorney Now:EBS@hbsslaw.com 844-916-0895

Emergent BioSolutions (NYSE: EBS) Securities Fraud Class Action:

Throughout the class period, Defendants touted Emergents deals with J&J and AstraZeneca worth a combined $875 million to produce their vaccine candidates and its separate $628 million production contract with the U.S. government as part of Operation Warp Speed. Defendants also emphasized Emergents preparedness to produce the vaccines, emphasizing its proven manufacturing capabilities in place at its Baltimore, Maryland facility.

In truth, the company failed to disclose a multitude of issues at its Baltimore facility that would detrimentally affect its ability to manufacture the vaccines.

On Mar. 31, 2021, media reports revealed the company mixed up ingredients for the two companies vaccines and contaminated up to 15 million doses of the J&J vaccine.

This news sent the price of Emergent shares crashing lower. Notably, shortly before the shares crashed the companys CEO sold about $10 million of his shares.

After the class period, on Apr. 6, 2021, the New York Times reported that [p]reviously undisclosed internal documents and interviews with current and former federal officials and former company employees depict a factory operation that was ill-equipped to take on such a mammoth manufacturing task. The NYT reported that audits and investigations including ones conducted by J&J, AstraZeneca, two federal agencies and Emergents own quality evaluators found that Emergent had not followed basic industry standards at its Baltimore facility. AstraZenicas audit highlighted risks of viral cross-contamination, which experts believe was responsible for the J&J vaccine contamination. The NYT further reported that beginning in Oct. 2020, Emergent discarded five lots of the AstraZenica vaccine and one lot of the J&J vaccine because of contamination or spoliation.

Were focused on investors losses and proving Emergent duped investors about its COVID-19 vaccine production capabilities and preparedness, said Reed Kathrein, the Hagens Berman partner leading the investigation.

If you are an Emergent investor and have significant losses, or have knowledge that may assist the firms investigation, click here to discuss your legal rights with Hagens Berman.

Whistleblowers: Persons with non-public information regarding Emergent should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email EBS@hbsslaw.com.

About Hagens BermanHagens Berman is a national law firm with eight offices in eight cities around the country and over eighty attorneys. The firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the firm and its successes is located at hbsslaw.com. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.

Contact: Reed Kathrein, 844-916-0895